Drug Database
ME

meningococcal polysaccharide vaccine (group A/C/Y/W135)

✓ Approved

Walvax Biotechnology · 疫苗 · 疫苗

什么是 meningococcal polysaccharide vaccine (group A/C/Y/W135)?

meningococcal polysaccharide vaccine (group A/C/Y/W135) 是一种疫苗,由Walvax Biotechnology研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

公司Walvax Biotechnology
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

治疗适应症

meningococcal polysaccharide vaccine (group A/C/Y/W135) 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedNPJ vaccines2026-11-19

Biosynthesis of a nanoscale Vibrio cholerae conjugate vaccine elicits potent immunity through size and receptor effects.

Wang Kangfeng K, Huang Jing J, Li Juntao J, Li Zhenshi Z et al.

Cholera, caused by Vibrio cholerae, remains a significant global health threat, with the O1 serotype being the predominant cause of recent global outbreaks. Although conjugate vaccines against V. cholerae have been developed via chemical methods, the feasibility of applying novel biosynthetic approaches remains uncertain due to the special structure of its O-polysaccharide, which should be recognized by oligosaccharyltransferases. Here, we successfully established an oligosaccharyltransferase PglL-based glycosylation system in an engineered V. cholerae strain to biosynthesize a nanoscale conjugate vaccine, NP-OPSVc(I). The carrier NP was designed by fusing the cholera toxin B subunit (CTB) with a trimer-forming protein (Tri), which could self‑assemble into a nanoparticle during expression. The resulting glycoprotein exhibited high purity, stability, and retained GM1-binding capacity. We found that the size of NP-OPSVc(I) and its GM1 receptor targeting both contribute to a potent humoral immune response, while its efficient delivery is additionally associated with the induction of intestinal mucosal immunity. In mouse models, the NP-OPSVc(I) demonstrated a favorable safety profile and elicited substantially stronger systemic and mucosal immune responses than conventional conjugates, providing great protection against lethal V. cholerae challenge even at a 10‑fold lower dose without requiring an adjuvant. Furthermore, the immune responses were confirmed in non-human primates, supporting its potential for clinical translation. This work not only developed a novel highly effective candidate vaccine against V. cholerae but also significantly expanded the application scope of the PglL-based platform technology, establishing it as a versatile and broadly applicable enzymatic toolkit for vaccine development.

PMID 43052362
阅读全文 →
PubMedNPJ vaccines2026-11-19

SARS-CoV-2 RBD fusion ameliorates enhanced disease induced by RSV G CCD mRNA vaccine in BALB/c mice.

Sun Yufang Y, Xie Ying Y, Liu Lian L, Yang Huijie H et al.

Respiratory syncytial virus (RSV) is a primary pathogen responsible for lower respiratory tract infections in both infants and the elderly. However, vaccine development has been consistently hampered by the risk of vaccine-enhanced disease (VED), while the role of the RSV attachment (G) glycoprotein has long been overlooked. Using an mRNA vaccine platform, this study systematically evaluated the roles of two critical RSV G protein domains-the central conserved domain (CCD) and the mucin-like domains-in mediating immune protection and VED. Results indicate that the mucin-like domains confer no protection and induce marked VED. Surprisingly, although CCD immunization elicits potent humoral immunity and significantly reduces viral load, it also induces Th2-biased responses and exacerbates pulmonary inflammation following RSV challenge. However, fusion of CCD with the receptor-binding domain (RBD) of SARS-CoV-2 in an mRNA vaccine (CCD + RBD) successfully redirected the Th2-biased immune responses toward a balanced Th1/Th2 profile, while significantly attenuating CCD-induced immunopathology. CD8⁺ T-cell depletion and adoptive-transfer experiments further supported a contribution of RBD-responsive CD8⁺ T cells to the reduction in pathology. These findings provide proof of concept that heterologous antigen fusion can reshape CCD-associated immunopathology in a BALB/c RSV challenge model.

PMID 43052326
阅读全文 →
PubMedNPJ Parkinson's disease2026-11-19

Kidney-inflammation-erythrocyte framework for Parkinson disease risk prediction and progression assessment.

Li Sigen S, Song Qiao Q, Zhou Sihan S, Li Wen W et al.

Parkinson's disease (PD) is increasingly recognized as a systemic disorder involving metabolic and peripheral pathological dysregulation. This study proposed a clinically accessible "Kidney-Inflammation-Erythrocyte" framework to characterize peripheral alterations in PD. We constructed and validated a nomogram for PD screening, identified factors associated with Hoehn and Yahr (H-Y) stages, and explored potential biological associations with disease progression using mediation analysis. 572 participants were included to examine the renal function markers, inflammatory indicators, and erythrocyte parameters. Firstly, after LASSO and multivariable logistic regression analysis, seven predictors, including age, sex, urea nitrogen, albumin, interleukin-6 (IL-6), C-reactive protein, and cystatin C, were used to build the nomogram, which showed good discrimination in the training and validation cohorts. Secondly, IL-6, cystatin C, and red blood cell count also showed stage-dependent changes across H-Y stages. Thirdly, after adjusting for age, sex, BMI, medication history, and comorbidities, mediation analysis showed significant total effects on H-Y stages, but no significant mediation pathways. In summary, this study demonstrates significant associations between the "Kidney-Inflammation-Erythrocyte" framework and PD, supporting the potential value of integrating routine laboratory markers for PD screening and disease monitoring. However, further mechanistic studies are needed to clarify how these peripheral alterations are associated with disease status and progression.

PMID 43052340
阅读全文 →
PubMedAJE advances : research in epidemiology2026-11-19

Estimating the population direct effect in cluster randomized trials of targeted interventions using contemporaneous counts in a non-target group.

Moore Kerryn A KA, Cheung Yin Bun YB, Fogelson Ari A, Milligan Paul P

In cluster randomized trials of interventions that target a subset of the at-risk population, contemporaneous event counts in a non-target group can be used to estimate the population direct effect if indirect effects are unlikely, but the application of this approach has been limited. We describe the rationale for using the contemporaneous counts approach in the WHO Malaria Vaccine Program Evaluation and how it was applied, and in a re-analysis of a human rotavirus vaccine trial, we demonstrate its application and compare results with conventional methods using event rates per unit of person-time. Indirect effects were considered unlikely because the target group represents a very small proportion of the at-risk population. The population direct effect of intervention introduction in the target group is estimated by comparing between arms the ratio of event counts in the target group to the non-target group. Expanding surveillance into a non-target group may often be possible without significant additional costs. Confounding due to chance imbalance is reduced implicitly insofar as there is better balance in the relative difference between the target and non-target groups than in the variable itself within the target group alone. The approach can improve efficiency when target group event counts are more strongly correlated with non-target-group counts than they are with target group person-time, which is more likely as heterogeneity increases. The contemporaneous counts approach can increase the efficiency and internal validity of cluster trials and reduce their operational complexity because person-time denominators are not required.

PMID 43053798
阅读全文 →
PubMedPflugers Archiv : European journal of physiology2026-11-19

Comparative physiological responses to self-paced exercise in men across age-training status: effort distribution, cerebral-muscle oxygenation and neuromuscular performance.

Chia Ee Von EV, Cannon Jack J, Marino Frank E FE

To compare self-paced cycling performance, effort distribution, and associated neuromuscular and physiological responses across three age-training phenotypes. Twenty-eight healthy men were classified as young trained (YT, n = 8; 26.3 ± 6.9 y), older trained (OT, n = 11; 57.5 ± 3.4 y), or young untrained (YU, n = 9; 24.8 ± 5.3 y). Participants completed a 25-min self-paced cycling time trial comprising five 4.5-min lower-intensity sections, each followed by a 30-s maximal sprint. Power output, heart rate (HR), rating of perceived exertion, blood lactate, core and skin temperature, cerebral and muscle tissue oxygenation, and pre/post knee-extensor neuromuscular function were assessed. Total distance differed between groups (P = 0.037), with OT cycling further than YU (12.87 ± 1.32 vs. 11.48 ± 0.89 km; mean difference 1.40 km, 95% CI 0.35-2.44; adjusted P = 0.035), whereas OT and YT did not differ. During lower-intensity sections, OT produced greater absolute power than YU (mean difference 51.8 W, 95% CI 18.8-84.7; adjusted P = 0.012). Sprint-power variability was lower in OT than YU (7.8 ± 6.0 vs. 28.4 ± 18.5%; adjusted P = 0.030). Peak HR was lower in OT than both younger groups. Voluntary activation showed no significant group x time interaction (P = 0.062), and NIRS responses showed no significant group x stage interactions. Older trained men achieved self-paced cycling performance comparable with young trained men and greater than young untrained men, characterised by sustained lower-intensity power and more stable sprint output despite a lower peak HR.

PMID 43052406
阅读全文 →
PubMedDiabetes, obesity & metabolism2026-11-19

Insulin Secretion Modelling to Characterize Post-Bariatric Hypoglycaemia After Roux-en-Y Gastric Bypass.

Mohammadi-Asl E E, El Fathi A A, Pei L L, Saeed H H et al.

Roux-en-Y Gastric Bypass (RYGB) is an effective treatment for obesity and Type 2 diabetes. Some individuals develop postprandial hypoglycaemia, termed post-bariatric hypoglycaemia (PBH). PBH is associated with marked postprandial increases in incretin and insulin levels. This study investigates how insulin secretion differs between post-RYGB patients with and without hypoglycaemia by identifying key secretion parameters. Insulin secretion was modelled using plasma glucose, insulin and C-peptide concentration data obtained from mixed meal tolerance test in three cohorts: healthy individuals without a history of upper gastrointestinal surgery (controls, n = 11), post-RYGB individuals without hypoglycaemia (RYGB-non-hypo, n = 18) and post-RYGB individuals with hypoglycaemia (RYGB-PBH, n = 20). Meal-driven insulin secretion differed across groups (p = 0.008) and was significantly higher in RYGB-PBH than controls (0.23 vs. 0.14 pmol/mg, p = 0.006), but not in RYGB-non-hypo (0.22, p = 0.071). Glucose-driven insulin secretion decreased in RYGB-non-hypo (0.04 vs. 0.07 pmol/kg/min per mg/dL, p = 0.005) but did not differ from controls in RYGB-PBH (0.08, p = 0.948), differing significantly between the two post-RYGB groups (p < 0.001). Meal absorption was significantly faster in both post-RYGB groups (9.08 and 8.44 vs. 11.48 min, both p < 0.001). Models fit plasma insulin and C-peptide well (mean joint nRMSE: 0.60-0.92 across groups). Parameters were estimated with good precision (CV < 100%). Insulin secretion dynamics differ between post-RYGB patients with and without hypoglycaemia. Both groups showed faster meal absorption and a shift towards higher meal-driven secretion, significant only in RYGB-PBH, but only those without hypoglycaemia showed a reduction in glucose-driven secretion. This PBH model can support in silico development of glucagon-based interventions.

PMID 43053530
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcal polysaccharide vaccine (group A/C/Y/W135)